PHARMACY

Camber launches generic Cozaar

BY David Salazar

PISCATAWAY, N.J. — Camber Pharmaceuticals on Tuesday announced that it had launched its portfolio of generic versions of Merck’s Cozaar (losartan potassium) tablets. The drug is indicated to treat high blood pressure. 
 
Camber’s losartan tablets will be available in 25-mg dosage strength — available in 90, 500 and 1,000 count bottles — and 50- and 100-mg dosage strength, both of which are available in bottles of 90 and 1,000. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Express Scripts, Imprimis partner on $1 Daraprim alternative

BY DSN STAFF

ST. LOUIS — Express Scripts announced Wednesday that it would be working with Imprimis Pharmaceuticals to provide a low-cost alternative to Daraprim — a drug meant to treat toxoplasmosis whose price went from $13.50 to $750 overnight when it was acquired by Turing Pharmaceuticals in September.

Imprimis will offer a compounded oral combination of pyrimethamine and leucovorin for $1 per capsule for patients whose benefits are managed by Express Scripts. The companies hope to start processing prescriptions for the formulation as early as this week.

“Leveraging our expertise to improve access and affordability to an important medication is the right thing to do for HIV patients and others who could benefit from a combination of pyrimethamine and leucovorin,” Express Scripts SVP and chief medical officer Dr. Steve Miller said. “We believe we now have an extremely cost-effective way to provide access to a Daraprim alternative. We will share our solution with other payers to make sure all appropriate patients around the country have access to the treatment they need at the lowest possible price.”

Express Scripts said it would work with such organizations as the Infectious Disease Society of America and the HIV Medicine Association to inform providers about the value of the formulation. To prescribe it, they write a patient-specific prescription for the combination of the two drugs to Imprimis, which will then compound it.

“We are pleased to partner with Express Scripts to take positive action to counterbalance companies like Turing and others in order to address the growing drug pricing crisis in America,” Imprimis CEO Mark Baum said. “Like Imprimis, Express Scripts believes in putting patients first and that the excessive drug price increases we have seen over the past few years, particularly for life saving medicines such as Daraprim, deserve our attention.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Sanofi rolls out new Priftin packaging

BY David Salazar

BRIDGEWATER, N.J. — Sanofi on Tuesday announced new 24- and 32-count packages for its Priftin (rifapentine), a treatment for latent tuberculosis infection in patients at high risk for tuberculosis and children older than 2 years of age.

Both packages contain blister packs with individually perforated tablet blisters and individual tablet printing on the backing foil. Both also come with an extended shelf life of up to three years.

“For more than fifty years, Sanofi has provided treatment and programs that equip patients and their healthcare providers to fight TB,” Sanofi’s global chief medical officer DR. Paul Chew said. “We are proud to introduce packaging and extended shelf-life that reinforces our sustained commitment to the TB community.”

According to Sanofi, patients with LTBI have the bacteria that causes TB, but wont’ show symptoms or feel sick, nor will they spread the disease. However, of the 13 million Americans with LTBI, some 5% to 10% will develop TB if they go untreated. Priftin is an antimycobacterial that can treat LTBI in combination with isoniazide. For information about who should get tested, see the infographic below. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?